The glucagonoma syndrome: A review of its features and discussion of new perspectives

American Journal of the Medical Sciences

Volumn 321, Issue 5, 2001, Pages 306-320

  Chastain, Mark A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Erythema; Glucagon; Glucagonoma; Paraneoplastic syndromes

Indexed keywords

AMINO ACID; FATTY ACID; GLUCAGON; OCTREOTIDE; ZINC;

ABDOMINAL DISCOMFORT; CHOLESTASIS; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GASTROINTESTINAL SYMPTOM; GLUCAGONOMA; HUMAN; INJECTION SITE; LIVER DISEASE; NEUROPSYCHIATRY; PANCREAS ISLET ALPHA CELL; PARANEOPLASTIC SYNDROME; PATHOGENESIS; ZINC DEFICIENCY;

EID: 0035023581     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200105000-00003     Document Type: Conference Paper

References (119)

1. Islet cell tumors
2. Carcinoma of the islets of the pancreas
3. Uber hauterscheinungen bei bosartigen geschwulsten innerer organe
4. Cutaneous manifestations of internal malignant tumors
5. Uber Argyrophile Zellen
6. Diabetes in a case of tumors of the islets of the pancreas
7. A glucagonsecreting alpha-cell carcinoma of the pancreas
8. Glucagon antibodies and immunoassay for glucagon
9. Necrolytic migratory erythema with carcinoma of the pancreas
10. A glucagonoma syndrome
11. Erytheme cutane migrateur avec necrose epidermique superficielle au cours d'une pancreatite chronique
12. Glucagonoma and pseudoglucagonoma syndromes
13. Iatrogenic necrolytic migratory erythema: A case report and review of nonglucagonoma-associated necrolytic migratory erythema
14. The glucagonoma syndrome. Clinical and pathologic features in 21 patients
15. Clinical aspects of glucagon-producing islet cell tumors
16. The glucagonoma syndrome
17. Functional endocrine tumors of the pancreas. Clinical presentation, diagnosis, and treatment
18. The glucagonoma syndrome. Clinical features, diagnosis, and treatment
19. Treatment of endocrine tumors of the pancreas
20. Rare presentation of endocrine pancreatic tumour: A case of glucagonoma without necrolytic migratory erythema?
21. The glucagonoma syndrome
22. Glucagonomas and insulinomas
23. Glucagonoma syndrome is an underdiagnosed entity
24. Gastroenteropancreatic endocrine tumors
25. The glucagonoma syndrome
26. Necrolytic migratory erythema and glucagon cell tumour of the pancreas: The glucagonoma syndrome
27. A dermatosis specifically associated with a tumour of pancreatic alpha cells
28. Necrolytic migratory erythema, presenting as candidiasis, due to a pancreatic glucagonoma
29. Dermatitis and nutritional deficiency
30. Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy
31. Cutaneous paraneoplastic syndromes in solid tumors
32. Necrolytic migratory erythema: Unresolved problems in diagnosis and pathogenesis. A case report and literature review
33. Necrolytic migratory erythema-like dermatitis with malabsorption
34. Angioplastic necrolytic migratory erythema. Unique association of necrolytic migratory erythema, extensive angioplasia, and high molecular weight glucagon-like polypeptide
35. 45-Year-old man with dermatitis and weight loss
36. th obligatory cutaneous paraneoplasia
37. Necrolytic migratory erythema: Dyskeratotic dermatitis, a clue to early diagnosis
38. Ultrastructural studies of necrolytic migratory erythema
39. Glucagonoma syndrome. Case report and literature review
40. Necrolytic migratory erythema. Distinctive dermatosis of the glucagonoma syndrome
41. Necrolytic acral erythema: A cutaneous marker of viral hepatitis C
42. Glucagonoma syndrome. A clinicopathologic, immunocytochemical, and ultrastructural study
43. Gastrointestinal endocrine tumors. Glucagonomas
44. Pancreatic glucagonoma with and without the syndrome: Immunocytochemical study of 5 tumour cases and review of the literature
45. A glucagonoma without necrolytic migratory erythema
46. Glucagonoma without cutaneous manifestations
47. Insulinoma and glucagonoma
48. Endocrine tumors of the pancreas and their clinical syndromes
49. The glucagonoma syndrome: Report of a case
50. A persistent periorificial eruption
51. Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma
52. Response of glucagonoma syndrome to lomustine
53. Retrobulbar neuritis as the first sign of the glucagonoma syndrome
54. Self-assessment examination of the American Academy of Dermatology
55. Glucagonoma as part of the polyglandular adenoma syndrome
56. Glucagonoma: An endocrine neoplasm with a unique dermatosis-necrolytic migratory erythema
57. Suprabasal acantholysis- and unusual feature of necrolytic migratory erythema
58. Cutaneous manifestations of nutritional deficiency states and gastrointestinal disease
59. Necrolytic migratory erythema in glucagonoma syndrome
60. Apoptosis with positive direct immunofluorescence findings in a patient with necrolytic migratory erythema
61. Histologic variation in the skin lesions of the glucagonoma syndrome
62. Necrolytic migratory erythema: Association with neuroendocrine tumour with predominant insulin secretion
63. In vivo and in vitro effects of somatostatin and insulin on glucagon release in a human glucagonoma
64. Localization of pancreatic endocrine tumors by endoscopic ultrasonography
65. A combined glucagonoma and VIPoma syndrome. First pathologic and clinical report
66. Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas
67. Aqueous extracts of the pancreas. Influence on the carbohydrate metabolism of depancreatized animals
68. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas
69. Purification and crystallization of hyperglycemic-glycogenolytic factor
70. Glucagon, glucagon-like peptide-1 and their receptors: An introduction
71. Glucagonoma tumors and syndrome
72. Glucagon and its family revisited
73. Rapid resolution of necrolytic migratory erythema after glucagonoma resection
74. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors
75. Glucagonoma syndrome: In vitro evidence that glucagon increases epidermal arachidonic acid
76. Necrolytic migratory erythema without glucagonoma in patients with liver disease
77. Hyperglucagonaemia and necrolytic migratory erythema in cirrhosis - Possible pseudoglucagonoma syndrome
78. Erythema necroticans migrans ohne glukagonom
79. Necrolytic migratory erythema: A report of three cases
80. Necrolytic migratory erythema with elevated plasma enteroglucagon in celiac disease
81. Necrolytic migratory erythema without glucagonoma
82. Atypical necrolytic migratory erythema in association with a jejunal adenocarcinoma
83. Erythema necrolyticum migrans after rectal adenocarcinoma
84. Necrolytic migratory erythema associated with odontogenic infection: An example of pseudoglucagonoma syndrome
85. Necrolytic migratory erythema without glucagonoma in a heroin-dependent patient
86. Skin rash in patient receiving glucagon
87. Pseudoglucagonoma syndrome: Case report, therapeutic possibilities and hypotheses on the etiology
88. Treatment with danazol and plasma glucagon concentration
89. Glucagon and amino acid disposal in normal man and in patients with cirrhosis
90. Glucagon secretion in acute and chronic pancreatitis
91. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: Is hepatic impairment a clue to pathogenesis?
92. Familial hyperglucagonemia - An autosomal dominant disorder
93. Superficial necrolytic dermatitis (necrolytic migratory erythema) in dogs
94. Ulcerative dermatosis associated with diabetes mellitus in the dog: A report of four cases
95. Necrolytic migratory erythema without glucagonoma: The role of dietary essential fatty acids
96. Necrolytic migratory erythema and zinc deficiency
97. Amino acid deficiency and the skin rash associated with glucagonoma
98. Disorders of absorption
99. The glucagonoma syndrome (necrolytic migratory erythema) and zinc
100. Immunological studies in a patient with the glucagonoma syndrome
101. Neurological involvement in glucagonoma syndrome
102. Immunohistochemical localization of factor X-like antigen in pancreatic islets and their turnouts
103. Response of glucagonomas to surgical excision and chemotherapy
104. Use of somatostatin analog (SMS 201-995) in the glucagonoma syndrome
105. Effect of somatostatin in necrolytic migratory erythema of glucagonoma
106. Glucagonoma syndrome with increased lactate dehydrogenase isoenzymes: Octreotide treatment
107. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth
108. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: Report of one case and review of the literature
109. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration
110. Slow-release lanreotide treatment in endocrine gastrointestinal tumors
111. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine
112. Dimethyltriazenoimidazole carboxamide therapy of islet cell carcinoma of the pancreas
113. Pancreatic islet cell carcinoma. Results of therapy with streptozotocin in 52 patients
114. Liver transplantation for primary and secondary hepatic apudomas
115. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas
116. Liver transplant for metastatic neuroendocrine tumor
117. Treatment of necrolytic migratory erythema in glucagonoma syndrome
118. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome
119. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema